
CHMP Provides Positive Opinion for MRD Negativity as an End Point for Regulatory Myeloma Clinical Trials
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has issued positive qualification advice to the novel biomarker procedure application submitted by the i2TEAMM and the International Myeloma Foundation regarding …